TNF and psoriasis: Hjuler et al. stated that biological therapy with anti-TNF agents (Adalimumab, Etanercept, Infliximab) or anti-IL12/23 (Ustekinumab) in patients with severe psoriasis decreases systemic inflammation, thus preventing coronary artery disease progression.